PEDRA is focused on developing perfusion technologies for the diagnosis and management of peripheral artery disease.
External link for PedraTech
Singapore, SG
Grateful to the Cedars Sinai Accelerator for physician feedback on our Xauron perfusion monitor.
So enjoyed the Singapore Innovation Week at the Cedars Sinai Accelerator in LA. Big thanks to Nirdesh, Colin, Omar, Julien, Kinshuk, Sam, Emily, Jenny, Mel, Michael, Sias, Delon, Mayank, Rithik, Howard, and all fellow SG entrepreneurs for the bonding and shared learning. Was a pleasure showing our perfusion monitor to Dr Donald Baril and his vascular colleagues at Cedars Sinai.
Two days into the Singapore Innovation Week at Cedars-Sinai Technology Ventures, and loving it!
Yesterday marked the beginning of our Singapore Innovation Week! Cedars-Sinai Technology Ventures and The Cedars-Sinai Accelerator kicked things off as we embarked on a fascinating tour of the main medical campus, exploring the cutting-edge facilities at the Women's Guild Simulation Center, and even reaching new heights at the helipad! Together with Coronet Ventures and Enterprise Singapore this Singapore Innovation Week will not only support companies in their U.S. go to market strategy, but explore crucial topics such as regulatory requirements, the role of internal review boards, and legal considerations for international companies. Check out the participating Singapore companies: BluMaiden Biosciences Carecam HiCura Medical Pte Ltd Kinexcs KroniKare Pte Ltd KYAN Technologies NalaGenetics Nousq Pte Ltd PedraTech Qritive TIIM Healthcare
PedraTech reposted this
Happy to be at Charing Cross Symposium with our CMO, Paul Hayes, and Larry Yost of the Atticus Group, as we show the capabilities of our real-time perfusion monitor to physician colleagues.
Sharing is caring! Thanks to the collaboration with Radcliffe Vascular, every Wednedsay morning, FYA will be with you.. One talk (and its fruitful intra-presentation discussion) will be uploaded every week... enjoy it for free and stay tuned! #fya #sharingiscaring Stephen Black, Dr Michael Lichtenberg, August Ysa, Efthymios (Makis) Avgerinos, Domenico Baccellieri, Tomas Baltrunas, Theodosios Bisdas, MD, PhD, FACS, Michel Bosiers, MD, Gonzalo Cabral, Emiliano Chisci, Patrick Fon Sen Chong, Edward Choke, Raphaël Coscas, Athanasios Diamantopoulos MD, PhD, FRCR, EBIR, FCIRSE, Gianmarco de Donato, Mert Dumantepe, Steve Elias, Stefano Fazzini, Roberto Ferraresi, Luca Garriboli, Manj Gohel, Giacomo Isernia, Houman Jalaie, Narayan Karunanithy, Prof. Dr. Grigorios Korosoglou, Tristan Lane, Ralf Langhoff, Hady Lichaa, MD, FACC, FSCAI, FSVM, RPVI, Lieven Maene, Stefano Michelagnoli, Paul Moxey, Bruno Migliara, Miguel Montero Baker, Robert M., Mark Portou, Bahaa Nasr, Craig Nesbitt, Isaac Nyamekye, Gerry O'Sullivan, Mariano Palena, Gianbattista Parlani, Ashish Patel, Paul Pittaluga, Mark Portou, Giovanni Pratesi, Barrie Price, Maria Antonella Ruffino, MD, EBIR, FCIRSE, Prakash Saha, Athanasios (Thanos) Saratzis, Peter Schneider, Michael Siah, Gioele Simonte, Jill Sommerset, Giovanni Torsello, Nada Selva Theivacumar, Narayan Thulasidasan, Conrad von Stempel, Mark Whiteley, HANY ZAYED, PEO - App. Your Personal Education Organizer
An important study indeed. It does hark to the potential need for a better metric than AFS for CLTI studies.
🚀 I am thrilled to announce the publication of our Phase 3 PACE study on Critical Limb Ischemia (CLI)! 💡Pluri has been dedicated to exploring novel therapeutic approaches to address CLI and improve patient outcomes. This publication marks a significant milestone in the mission to advance vascular health and enhance the quality of life for individuals affected by CLI. 🌟 We're immensely grateful to our collaborators, sponsors, and most importantly, the patients who participated in this study. 📖 For those interested in diving deeper into the details of our research, the paper is now available in the British Journal of Surgery (https://lnkd.in/dwdi9nCs) and featured in the editorial (https://lnkd.in/dvKwJzuD). 🤝 Let's continue to collaborate, innovate, and make meaningful strides towards better healthcare outcomes for all. Together, we can make a difference in the lives of those impacted by critical limb ischemia. #CLI #VascularHealth #MedicalAdvancements #HealthcareInnovation #celltherapy
Planning to be there...
Is your start-up technology within the vascular field? Are you interested to pitch at LINC 2024 during a dedicated Start-up village in front of hundreds of KOLs and industry? If yes, please send us an application email to scout@medtech-sharktank.eu or in case you would like to receive some more information. Four hours of dedicated Start-up technology discussion during LINC 2024! We are looking forward to your application Michael Lichtenberg, Peter Schneider and Dierk Scheinert PEO - App. Your Personal Education Organizer
Patency is good, perfusion is better. Some conclusions from the latest attached article on BEST-CLI: "...beyond the improvement of conduit patency, there remain significant major unmet clinical needs. These include a reliable and reproducible measure of tissue perfusion...” “Ongoing research in this domain would enhance care from both endovascular and surgical revascularization standpoints, by addressing the fundamental issue of how much perfusion is enough to heal an ischaemic limb.” “Having such information [perfusion] would provide more concrete endpoints to procedures and guide appropriate use of adjuncts to achieve those endpoints.” “Moreover, during the convalescence phase after revascularization, such data could guide strategic reintervention, especially when subclinical ischaemia precedes significant symptoms" To our physician friends and supporters, we've been under the radar for a while to perfect our real-time quantitative perfusion monitor. Cath lab case studies are looking pretty good. We're almost there.